Zanidatamab is a cytolytic bispecific IgG1-like HER2-directed mAb indicated for adult patients who have previously treated unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test [58]. Here, ERBB2 is linked to biliary tract neoplasm.